We are analyzing https://link.springer.com/article/10.1007/s12265-014-9605-1.

Title:
Development of Lipoprotein(a) siRNAs for Mechanism of Action Studies in Non-Human Primate Models of Atherosclerosis | Journal of Cardiovascular Translational Research
Description:
Lipoprotein(a) [Lp(a)] has recently been recognized as an independent risk factor for coronary heart disease. While plasma Lp(a) levels are correlated with cardiovascular risk, the mechanism by which this particle contributes to atherosclerosis is largely unknown. Although humanized transgenic mouse model has recently been described to study Lp(a) biology, non-human primates (NHP) are the only preclinical model available that allow study of the role of Lp(a) in atherosclerosis in an innate setting. We describe targeting of LPA using lipid nanoparticle formulated short interfering RNAs (siRNAs) in lean rhesus macaque monkeys. We show >90 % LPA mRNA lowering in the liver and >95 % Lp(a) plasma reduction for over 3 weeks after a single siRNA dose. Given the potency of LPA siRNAs, siRNA approach may enable chronic reduction of Lp(a) in atherosclerotic NHP and help to unmask the role for Lp(a) in the genesis and progression of atherosclerosis in man.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't see how the site brings in money.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Link.springer.com could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {🔍}

article, pubmed, google, scholar, cas, lpa, journal, lipoproteina, atherosclerosis, sirna, research, human, lipoprotein, apolipoproteina, central, plasma, cardiovascular, sirnas, tadinstrapps, disease, apolipoprotein, nature, mice, rna, silencing, development, nonhuman, coronary, transgenic, lipid, access, molecular, usa, privacy, cookies, content, studies, marija, risk, heart, levels, nhp, role, interfering, therapeutics, cholesterol, medicine, tsimikas, marcovina, miller,

Topics {✒️}

month download article/chapter low-density lipoprotein cholesterol lectin-bound plasma fraction extensive atherosclerotic lesions large-scale prospective data vivo anti-hbv activity article tadin-strapps marija tadin-strapps rnai-mediated gene silencing apolipoprotein b-100 particles full article pdf nucleic acids research alpha-cyclodextrin sulfate privacy choices/manage cookies human primate models rna therapeutics provide lauretta le voci merck research labs antisense oligonucleotide directed independent risk factor dgat2 sirna silencing related subjects whhl transgenic rabbits sirna formulation team sirna pm team biophysical research communications major lipid classes lpa gene silencing fatty lesions single sirna dose nasally administered sirna systemically administered sirna potent sirna nanoparticle ccr2-/- mice reveals generating lnp formulations nhp models ldl coronary heart disease european economic area lori andrews satya yendluri rodent myeloid cells guide strand overhangs decreased lesion formation arterial wall influx luciferase clone construct wholly owned subsidiary electronic supplementary material coronary artery disease cholesterol-rich diet combat cardiovascular disease

Questions {❓}

Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Development of Lipoprotein(a) siRNAs for Mechanism of Action Studies in Non-Human Primate Models of Atherosclerosis
         description:Lipoprotein(a) [Lp(a)] has recently been recognized as an independent risk factor for coronary heart disease. While plasma Lp(a) levels are correlated with cardiovascular risk, the mechanism by which this particle contributes to atherosclerosis is largely unknown. Although humanized transgenic mouse model has recently been described to study Lp(a) biology, non-human primates (NHP) are the only preclinical model available that allow study of the role of Lp(a) in atherosclerosis in an innate setting. We describe targeting of LPA using lipid nanoparticle formulated short interfering RNAs (siRNAs) in lean rhesus macaque monkeys. We show >90 % LPA mRNA lowering in the liver and >95 % Lp(a) plasma reduction for over 3 weeks after a single siRNA dose. Given the potency of LPA siRNAs, siRNA approach may enable chronic reduction of Lp(a) in atherosclerotic NHP and help to unmask the role for Lp(a) in the genesis and progression of atherosclerosis in man.
         datePublished:2015-01-21T00:00:00Z
         dateModified:2015-01-21T00:00:00Z
         pageStart:44
         pageEnd:53
         sameAs:https://doi.org/10.1007/s12265-014-9605-1
         keywords:
            Apo(a)
            Lp(a)
            NHP models
            LDL-c lowering
            Atherosclerosis
            siRNA
            LNP
            RNAi
            Cardiology
            Human Genetics
            Biomedical Engineering and Bioengineering
            Biomedicine
            general
            Medicine/Public Health
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12265-014-9605-1/MediaObjects/12265_2014_9605_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12265-014-9605-1/MediaObjects/12265_2014_9605_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12265-014-9605-1/MediaObjects/12265_2014_9605_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12265-014-9605-1/MediaObjects/12265_2014_9605_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12265-014-9605-1/MediaObjects/12265_2014_9605_Fig5_HTML.gif
         isPartOf:
            name:Journal of Cardiovascular Translational Research
            issn:
               1937-5395
               1937-5387
            volumeNumber:8
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Marija Tadin-Strapps
               affiliation:
                     name:Merck Sharp & Dohme Corp.
                     address:
                        name:RNA Therapeutics, Merck Sharp & Dohme Corp., West Point, USA
                        type:PostalAddress
                     type:Organization
                     name:Merck Sharp & Dohme Corp.
                     address:
                        name:Department of Genetics and Pharmacogenomics, Merck Sharp & Dohme Corp., Boston, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Michael Robinson
               affiliation:
                     name:Sirna Therapeutics Inc., a Wholly Owned Subsidiary of Merck Sharp & Dohme Corp.
                     address:
                        name:Sirna Therapeutics Inc., a Wholly Owned Subsidiary of Merck Sharp & Dohme Corp., San Francisco, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Lauretta Le Voci
               affiliation:
                     name:Merck Sharp & Dohme Corp.
                     address:
                        name:Division of Cardiovascular Diseases, Merck Sharp & Dohme Corp., Kenilworth, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Lori Andrews
               affiliation:
                     name:Sirna Therapeutics Inc., a Wholly Owned Subsidiary of Merck Sharp & Dohme Corp.
                     address:
                        name:Sirna Therapeutics Inc., a Wholly Owned Subsidiary of Merck Sharp & Dohme Corp., San Francisco, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Satya Yendluri
               affiliation:
                     name:Sirna Therapeutics Inc., a Wholly Owned Subsidiary of Merck Sharp & Dohme Corp.
                     address:
                        name:Sirna Therapeutics Inc., a Wholly Owned Subsidiary of Merck Sharp & Dohme Corp., San Francisco, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Stephanie Williams
               affiliation:
                     name:Merck Sharp & Dohme Corp.
                     address:
                        name:RNA Therapeutics, Merck Sharp & Dohme Corp., West Point, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Steve Bartz
               affiliation:
                     name:Merck Research Labs
                     address:
                        name:External Scientific Affairs, Merck Research Labs, Rahway, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Douglas G. Johns
               affiliation:
                     name:Merck Sharp & Dohme Corp.
                     address:
                        name:Division of Cardiovascular Diseases, Merck Sharp & Dohme Corp., Kenilworth, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Development of Lipoprotein(a) siRNAs for Mechanism of Action Studies in Non-Human Primate Models of Atherosclerosis
      description:Lipoprotein(a) [Lp(a)] has recently been recognized as an independent risk factor for coronary heart disease. While plasma Lp(a) levels are correlated with cardiovascular risk, the mechanism by which this particle contributes to atherosclerosis is largely unknown. Although humanized transgenic mouse model has recently been described to study Lp(a) biology, non-human primates (NHP) are the only preclinical model available that allow study of the role of Lp(a) in atherosclerosis in an innate setting. We describe targeting of LPA using lipid nanoparticle formulated short interfering RNAs (siRNAs) in lean rhesus macaque monkeys. We show >90 % LPA mRNA lowering in the liver and >95 % Lp(a) plasma reduction for over 3 weeks after a single siRNA dose. Given the potency of LPA siRNAs, siRNA approach may enable chronic reduction of Lp(a) in atherosclerotic NHP and help to unmask the role for Lp(a) in the genesis and progression of atherosclerosis in man.
      datePublished:2015-01-21T00:00:00Z
      dateModified:2015-01-21T00:00:00Z
      pageStart:44
      pageEnd:53
      sameAs:https://doi.org/10.1007/s12265-014-9605-1
      keywords:
         Apo(a)
         Lp(a)
         NHP models
         LDL-c lowering
         Atherosclerosis
         siRNA
         LNP
         RNAi
         Cardiology
         Human Genetics
         Biomedical Engineering and Bioengineering
         Biomedicine
         general
         Medicine/Public Health
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12265-014-9605-1/MediaObjects/12265_2014_9605_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12265-014-9605-1/MediaObjects/12265_2014_9605_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12265-014-9605-1/MediaObjects/12265_2014_9605_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12265-014-9605-1/MediaObjects/12265_2014_9605_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12265-014-9605-1/MediaObjects/12265_2014_9605_Fig5_HTML.gif
      isPartOf:
         name:Journal of Cardiovascular Translational Research
         issn:
            1937-5395
            1937-5387
         volumeNumber:8
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Marija Tadin-Strapps
            affiliation:
                  name:Merck Sharp & Dohme Corp.
                  address:
                     name:RNA Therapeutics, Merck Sharp & Dohme Corp., West Point, USA
                     type:PostalAddress
                  type:Organization
                  name:Merck Sharp & Dohme Corp.
                  address:
                     name:Department of Genetics and Pharmacogenomics, Merck Sharp & Dohme Corp., Boston, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Michael Robinson
            affiliation:
                  name:Sirna Therapeutics Inc., a Wholly Owned Subsidiary of Merck Sharp & Dohme Corp.
                  address:
                     name:Sirna Therapeutics Inc., a Wholly Owned Subsidiary of Merck Sharp & Dohme Corp., San Francisco, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Lauretta Le Voci
            affiliation:
                  name:Merck Sharp & Dohme Corp.
                  address:
                     name:Division of Cardiovascular Diseases, Merck Sharp & Dohme Corp., Kenilworth, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Lori Andrews
            affiliation:
                  name:Sirna Therapeutics Inc., a Wholly Owned Subsidiary of Merck Sharp & Dohme Corp.
                  address:
                     name:Sirna Therapeutics Inc., a Wholly Owned Subsidiary of Merck Sharp & Dohme Corp., San Francisco, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Satya Yendluri
            affiliation:
                  name:Sirna Therapeutics Inc., a Wholly Owned Subsidiary of Merck Sharp & Dohme Corp.
                  address:
                     name:Sirna Therapeutics Inc., a Wholly Owned Subsidiary of Merck Sharp & Dohme Corp., San Francisco, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Stephanie Williams
            affiliation:
                  name:Merck Sharp & Dohme Corp.
                  address:
                     name:RNA Therapeutics, Merck Sharp & Dohme Corp., West Point, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Steve Bartz
            affiliation:
                  name:Merck Research Labs
                  address:
                     name:External Scientific Affairs, Merck Research Labs, Rahway, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Douglas G. Johns
            affiliation:
                  name:Merck Sharp & Dohme Corp.
                  address:
                     name:Division of Cardiovascular Diseases, Merck Sharp & Dohme Corp., Kenilworth, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Journal of Cardiovascular Translational Research
      issn:
         1937-5395
         1937-5387
      volumeNumber:8
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Merck Sharp & Dohme Corp.
      address:
         name:RNA Therapeutics, Merck Sharp & Dohme Corp., West Point, USA
         type:PostalAddress
      name:Merck Sharp & Dohme Corp.
      address:
         name:Department of Genetics and Pharmacogenomics, Merck Sharp & Dohme Corp., Boston, USA
         type:PostalAddress
      name:Sirna Therapeutics Inc., a Wholly Owned Subsidiary of Merck Sharp & Dohme Corp.
      address:
         name:Sirna Therapeutics Inc., a Wholly Owned Subsidiary of Merck Sharp & Dohme Corp., San Francisco, USA
         type:PostalAddress
      name:Merck Sharp & Dohme Corp.
      address:
         name:Division of Cardiovascular Diseases, Merck Sharp & Dohme Corp., Kenilworth, USA
         type:PostalAddress
      name:Sirna Therapeutics Inc., a Wholly Owned Subsidiary of Merck Sharp & Dohme Corp.
      address:
         name:Sirna Therapeutics Inc., a Wholly Owned Subsidiary of Merck Sharp & Dohme Corp., San Francisco, USA
         type:PostalAddress
      name:Sirna Therapeutics Inc., a Wholly Owned Subsidiary of Merck Sharp & Dohme Corp.
      address:
         name:Sirna Therapeutics Inc., a Wholly Owned Subsidiary of Merck Sharp & Dohme Corp., San Francisco, USA
         type:PostalAddress
      name:Merck Sharp & Dohme Corp.
      address:
         name:RNA Therapeutics, Merck Sharp & Dohme Corp., West Point, USA
         type:PostalAddress
      name:Merck Research Labs
      address:
         name:External Scientific Affairs, Merck Research Labs, Rahway, USA
         type:PostalAddress
      name:Merck Sharp & Dohme Corp.
      address:
         name:Division of Cardiovascular Diseases, Merck Sharp & Dohme Corp., Kenilworth, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Marija Tadin-Strapps
      affiliation:
            name:Merck Sharp & Dohme Corp.
            address:
               name:RNA Therapeutics, Merck Sharp & Dohme Corp., West Point, USA
               type:PostalAddress
            type:Organization
            name:Merck Sharp & Dohme Corp.
            address:
               name:Department of Genetics and Pharmacogenomics, Merck Sharp & Dohme Corp., Boston, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Michael Robinson
      affiliation:
            name:Sirna Therapeutics Inc., a Wholly Owned Subsidiary of Merck Sharp & Dohme Corp.
            address:
               name:Sirna Therapeutics Inc., a Wholly Owned Subsidiary of Merck Sharp & Dohme Corp., San Francisco, USA
               type:PostalAddress
            type:Organization
      name:Lauretta Le Voci
      affiliation:
            name:Merck Sharp & Dohme Corp.
            address:
               name:Division of Cardiovascular Diseases, Merck Sharp & Dohme Corp., Kenilworth, USA
               type:PostalAddress
            type:Organization
      name:Lori Andrews
      affiliation:
            name:Sirna Therapeutics Inc., a Wholly Owned Subsidiary of Merck Sharp & Dohme Corp.
            address:
               name:Sirna Therapeutics Inc., a Wholly Owned Subsidiary of Merck Sharp & Dohme Corp., San Francisco, USA
               type:PostalAddress
            type:Organization
      name:Satya Yendluri
      affiliation:
            name:Sirna Therapeutics Inc., a Wholly Owned Subsidiary of Merck Sharp & Dohme Corp.
            address:
               name:Sirna Therapeutics Inc., a Wholly Owned Subsidiary of Merck Sharp & Dohme Corp., San Francisco, USA
               type:PostalAddress
            type:Organization
      name:Stephanie Williams
      affiliation:
            name:Merck Sharp & Dohme Corp.
            address:
               name:RNA Therapeutics, Merck Sharp & Dohme Corp., West Point, USA
               type:PostalAddress
            type:Organization
      name:Steve Bartz
      affiliation:
            name:Merck Research Labs
            address:
               name:External Scientific Affairs, Merck Research Labs, Rahway, USA
               type:PostalAddress
            type:Organization
      name:Douglas G. Johns
      affiliation:
            name:Merck Sharp & Dohme Corp.
            address:
               name:Division of Cardiovascular Diseases, Merck Sharp & Dohme Corp., Kenilworth, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:RNA Therapeutics, Merck Sharp & Dohme Corp., West Point, USA
      name:Department of Genetics and Pharmacogenomics, Merck Sharp & Dohme Corp., Boston, USA
      name:Sirna Therapeutics Inc., a Wholly Owned Subsidiary of Merck Sharp & Dohme Corp., San Francisco, USA
      name:Division of Cardiovascular Diseases, Merck Sharp & Dohme Corp., Kenilworth, USA
      name:Sirna Therapeutics Inc., a Wholly Owned Subsidiary of Merck Sharp & Dohme Corp., San Francisco, USA
      name:Sirna Therapeutics Inc., a Wholly Owned Subsidiary of Merck Sharp & Dohme Corp., San Francisco, USA
      name:RNA Therapeutics, Merck Sharp & Dohme Corp., West Point, USA
      name:External Scientific Affairs, Merck Research Labs, Rahway, USA
      name:Division of Cardiovascular Diseases, Merck Sharp & Dohme Corp., Kenilworth, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(174)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.18s.

LINK . SPRINGER . COM {}